The design of our DoxFILN is based on our finding that only TNBC patients with high intratumoral transcription of both IL15 and IL2RG have a favorable prognosis than those with low transcription of the two genes, which indicates that effective anti‐tumor immune surveillance requires the infiltration and activation of effector cells. The gene discussed is IL15; the disease is neoplasm.